Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 33 | 2024 | 761 | 8.450 |
Why?
|
| Candidemia | 12 | 2024 | 39 | 5.370 |
Why?
|
| Drug Resistance, Fungal | 22 | 2024 | 77 | 5.120 |
Why?
|
| Candida glabrata | 8 | 2024 | 38 | 4.950 |
Why?
|
| Echinocandins | 11 | 2024 | 53 | 3.810 |
Why?
|
| Fluconazole | 12 | 2024 | 156 | 3.580 |
Why?
|
| Candida | 7 | 2023 | 172 | 2.730 |
Why?
|
| Candidiasis | 8 | 2024 | 367 | 2.590 |
Why?
|
| Microbial Sensitivity Tests | 27 | 2024 | 1965 | 2.400 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 8 | 2021 | 506 | 1.470 |
Why?
|
| Saccharomycetales | 3 | 2021 | 74 | 1.440 |
Why?
|
| Fungemia | 2 | 2020 | 57 | 1.310 |
Why?
|
| Yeasts | 2 | 2020 | 279 | 1.220 |
Why?
|
| Mycoses | 3 | 2022 | 386 | 1.170 |
Why?
|
| Iran | 10 | 2021 | 760 | 1.160 |
Why?
|
| Amplified Fragment Length Polymorphism Analysis | 6 | 2020 | 10 | 1.050 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2019 | 614 | 0.890 |
Why?
|
| Mycological Typing Techniques | 3 | 2020 | 10 | 0.870 |
Why?
|
| DNA, Ribosomal | 3 | 2019 | 301 | 0.870 |
Why?
|
| Candida tropicalis | 2 | 2020 | 6 | 0.770 |
Why?
|
| Trichosporon | 1 | 2021 | 9 | 0.770 |
Why?
|
| Molecular Typing | 2 | 2019 | 116 | 0.760 |
Why?
|
| Madurella | 1 | 2020 | 4 | 0.700 |
Why?
|
| Mycetoma | 1 | 2020 | 18 | 0.680 |
Why?
|
| Serum | 1 | 2018 | 208 | 0.570 |
Why?
|
| Sequence Analysis, DNA | 5 | 2020 | 4780 | 0.560 |
Why?
|
| Turkey | 3 | 2021 | 256 | 0.520 |
Why?
|
| Meningitis, Cryptococcal | 3 | 2021 | 67 | 0.510 |
Why?
|
| Genotype | 6 | 2024 | 13047 | 0.500 |
Why?
|
| Candida albicans | 1 | 2018 | 376 | 0.500 |
Why?
|
| DNA, Fungal | 3 | 2020 | 276 | 0.440 |
Why?
|
| Azoles | 2 | 2023 | 23 | 0.410 |
Why?
|
| Macrophages | 2 | 2024 | 5797 | 0.390 |
Why?
|
| Fungi | 3 | 2024 | 346 | 0.360 |
Why?
|
| Nanofibers | 2 | 2021 | 68 | 0.350 |
Why?
|
| Amphotericin B | 3 | 2022 | 143 | 0.350 |
Why?
|
| Genetic Variation | 3 | 2020 | 6610 | 0.350 |
Why?
|
| DNA, Intergenic | 2 | 2020 | 108 | 0.320 |
Why?
|
| Sensitivity and Specificity | 7 | 2022 | 14728 | 0.310 |
Why?
|
| Drug Resistance, Multiple, Fungal | 2 | 2024 | 10 | 0.290 |
Why?
|
| Molecular Epidemiology | 2 | 2020 | 473 | 0.290 |
Why?
|
| Fungal Proteins | 4 | 2024 | 908 | 0.240 |
Why?
|
| Disease Outbreaks | 4 | 2024 | 1764 | 0.240 |
Why?
|
| DNA Primers | 2 | 2019 | 2826 | 0.240 |
Why?
|
| Treatment Failure | 2 | 2021 | 2656 | 0.230 |
Why?
|
| Vagina | 2 | 2019 | 845 | 0.220 |
Why?
|
| Humans | 42 | 2024 | 768451 | 0.210 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2022 | 18 | 0.210 |
Why?
|
| Genetic Fitness | 1 | 2024 | 120 | 0.210 |
Why?
|
| Candidiasis, Invasive | 1 | 2022 | 24 | 0.200 |
Why?
|
| Talaromyces | 1 | 2022 | 10 | 0.200 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2022 | 48 | 0.200 |
Why?
|
| Arthrodermataceae | 1 | 2020 | 7 | 0.190 |
Why?
|
| Drug Tolerance | 1 | 2023 | 367 | 0.190 |
Why?
|
| Mucormycosis | 1 | 2022 | 102 | 0.180 |
Why?
|
| Dermatomycoses | 1 | 2020 | 48 | 0.180 |
Why?
|
| Drugs, Investigational | 1 | 2022 | 213 | 0.170 |
Why?
|
| Child | 10 | 2024 | 80863 | 0.170 |
Why?
|
| Polyvinyl Alcohol | 1 | 2020 | 74 | 0.170 |
Why?
|
| Geotrichum | 1 | 2018 | 4 | 0.160 |
Why?
|
| Chitosan | 1 | 2020 | 141 | 0.160 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 131 | 0.160 |
Why?
|
| Mutation | 6 | 2024 | 30243 | 0.160 |
Why?
|
| Gelatin | 1 | 2020 | 230 | 0.150 |
Why?
|
| Adolescent | 10 | 2024 | 89168 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 277 | 0.150 |
Why?
|
| Aspergillus | 1 | 2017 | 95 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2023 | 81834 | 0.140 |
Why?
|
| Shigella | 1 | 2017 | 69 | 0.140 |
Why?
|
| Spinal Puncture | 1 | 2019 | 286 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2023 | 1599 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2024 | 42623 | 0.140 |
Why?
|
| Intracranial Hypertension | 1 | 2019 | 193 | 0.140 |
Why?
|
| Diabetic Foot | 1 | 2021 | 383 | 0.140 |
Why?
|
| Nephrotic Syndrome | 1 | 2020 | 382 | 0.130 |
Why?
|
| Infant | 5 | 2022 | 36497 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 20231 | 0.130 |
Why?
|
| Developing Countries | 2 | 2019 | 2901 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 59680 | 0.130 |
Why?
|
| Middle Aged | 12 | 2024 | 223418 | 0.130 |
Why?
|
| beta-Lactamases | 1 | 2017 | 307 | 0.130 |
Why?
|
| Male | 15 | 2024 | 364781 | 0.130 |
Why?
|
| Phylogeny | 2 | 2020 | 2846 | 0.120 |
Why?
|
| Hand | 1 | 2020 | 907 | 0.120 |
Why?
|
| Cross Infection | 2 | 2024 | 1425 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 1195 | 0.120 |
Why?
|
| Aged | 8 | 2024 | 171520 | 0.120 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 704 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2019 | 1840 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 7471 | 0.110 |
Why?
|
| Species Specificity | 1 | 2018 | 2422 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2020 | 1575 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 1474 | 0.110 |
Why?
|
| Triazoles | 1 | 2019 | 905 | 0.110 |
Why?
|
| Drainage | 1 | 2019 | 1179 | 0.110 |
Why?
|
| Genome | 1 | 2021 | 1749 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 5887 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.100 |
Why?
|
| Young Adult | 6 | 2024 | 60045 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2731 | 0.100 |
Why?
|
| Female | 13 | 2024 | 396943 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2023 | 26395 | 0.090 |
Why?
|
| Diarrhea | 1 | 2017 | 1320 | 0.090 |
Why?
|
| China | 3 | 2022 | 2398 | 0.090 |
Why?
|
| Adult | 9 | 2024 | 223542 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 6091 | 0.080 |
Why?
|
| Escherichia coli | 2 | 2021 | 4220 | 0.080 |
Why?
|
| Mice | 3 | 2024 | 82045 | 0.080 |
Why?
|
| Biopsy | 1 | 2020 | 6816 | 0.070 |
Why?
|
| Software | 1 | 2021 | 4463 | 0.070 |
Why?
|
| Animals | 5 | 2024 | 169418 | 0.060 |
Why?
|
| Hospitals | 1 | 2019 | 3906 | 0.060 |
Why?
|
| Prognosis | 3 | 2022 | 30028 | 0.060 |
Why?
|
| HIV Infections | 2 | 2022 | 17564 | 0.060 |
Why?
|
| Mannans | 1 | 2022 | 58 | 0.050 |
Why?
|
| Glucans | 1 | 2022 | 71 | 0.050 |
Why?
|
| Cilastatin | 1 | 2021 | 12 | 0.050 |
Why?
|
| Imipenem | 1 | 2021 | 37 | 0.050 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2020 | 28 | 0.050 |
Why?
|
| Galactose | 1 | 2022 | 299 | 0.050 |
Why?
|
| Sequence Analysis | 1 | 2021 | 240 | 0.040 |
Why?
|
| Algeria | 1 | 2020 | 5 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 54914 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 162 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2021 | 265 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2022 | 762 | 0.040 |
Why?
|
| HIV Seronegativity | 1 | 2021 | 211 | 0.040 |
Why?
|
| X-Ray Diffraction | 1 | 2020 | 418 | 0.040 |
Why?
|
| Glucosyltransferases | 1 | 2019 | 94 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2022 | 1706 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2024 | 65409 | 0.040 |
Why?
|
| Brazil | 1 | 2022 | 1247 | 0.040 |
Why?
|
| Environmental Microbiology | 1 | 2017 | 47 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 784 | 0.040 |
Why?
|
| Vancomycin | 1 | 2021 | 506 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2021 | 1421 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 12242 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2017 | 242 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 1158 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2022 | 2865 | 0.030 |
Why?
|
| Infection Control | 1 | 2020 | 985 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 1461 | 0.030 |
Why?
|
| Prevalence | 2 | 2020 | 15880 | 0.020 |
Why?
|
| Feces | 1 | 2017 | 1515 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2020 | 5904 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 13452 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2020 | 2601 | 0.020 |
Why?
|
| Mortality | 1 | 2021 | 2917 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2022 | 3805 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 26351 | 0.020 |
Why?
|
| Length of Stay | 1 | 2021 | 6521 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7605 | 0.020 |
Why?
|
| Health Personnel | 1 | 2020 | 3384 | 0.020 |
Why?
|
| Comorbidity | 1 | 2021 | 10601 | 0.020 |
Why?
|
| Pandemics | 1 | 2022 | 8753 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 22293 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 13497 | 0.010 |
Why?
|
| Risk Factors | 1 | 2022 | 74915 | 0.010 |
Why?
|
Concepts
(158)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_